Goldman Sachs’s Enzo Biochem, Inc. ENZ Stock Holding History

Goldman Sachs’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-17,473	Closed	-$39K	–	6311
2022 Q3	$39K	Sell	17,473 -3,649	-17%	-$8.81K	﹤0.01%	5827
2022 Q2	$44K	Sell	21,122 -7,903	-27%	-$19.5K	﹤0.01%	6054
2022 Q1	$84K	Sell	29,025 -1,016	-3%	-$3.26K	﹤0.01%	6159
2021 Q4	$96K	Sell	30,041 -15,122	-33%	-$51.6K	﹤0.01%	6145
2021 Q3	$160K	Sell	45,163 -30,483	-40%	-$102K	﹤0.01%	5796
2021 Q2	$240K	Sell	75,646 -2,493	-3%	-$7.84K	﹤0.01%	5650
2021 Q1	$269K	Buy	78,139 +19,861	+34%	+$61.8K	﹤0.01%	5484
2020 Q4	$147K	Sell	58,278 -32,397	-36%	-$70.6K	﹤0.01%	5190
2020 Q3	$191K	Sell	90,675 -24,037	-21%	-$57.1K	﹤0.01%	4933
2020 Q2	$257K	Buy	114,712 +53,418	+87%	+$137K	﹤0.01%	4693
2020 Q1	$155K	Buy	61,294 +13,111	+27%	+$32.2K	﹤0.01%	4795
2019 Q4	$126K	Buy	48,183 +11,780	+32%	+$35.2K	﹤0.01%	5013
2019 Q3	$131K	Sell	36,403 -83,923	-70%	-$297K	﹤0.01%	4924
2019 Q2	$406K	Buy	120,326 +35,766	+42%	+$126K	﹤0.01%	4481
2019 Q1	$231K	Sell	84,560 -17,907	-17%	-$58.6K	﹤0.01%	4741
2018 Q4	$285K	Buy	102,467 +9,587	+10%	+$31.4K	﹤0.01%	4660
2018 Q3	$383K	Sell	92,880 -33,035	-26%	-$150K	﹤0.01%	4566
2018 Q2	$653K	Sell	125,915 -94,899	-43%	-$578K	﹤0.01%	4350
2018 Q1	$1.21M	Buy	220,814 +70,960	+47%	+$500K	﹤0.01%	3926
2017 Q4	$1.22M	Buy	149,854 +7,231	+5%	+$69.1K	﹤0.01%	4180
2017 Q3	$1.49M	Sell	142,623 -63,611	-31%	-$706K	﹤0.01%	4233
2017 Q2	$2.28M	Buy	206,234 +86,595	+72%	+$807K	﹤0.01%	3744
2017 Q1	$1M	Sell	119,639 -6,885	-5%	-$48.5K	﹤0.01%	4375
2016 Q4	$878K	Buy	126,524 +14,425	+13%	+$92.1K	﹤0.01%	4573
2016 Q3	$571K	Buy	112,099 +77,703	+226%	+$464K	﹤0.01%	4924
2016 Q2	$205K	Sell	34,396 -139,165	-80%	-$772K	﹤0.01%	5675
2016 Q1	$790K	Buy	173,561 +67,322	+63%	+$300K	﹤0.01%	4296
2015 Q4	$478K	Sell	106,239 -32,738	-24%	-$138K	﹤0.01%	4968
2015 Q3	$441K	Sell	138,977 -165,022	-54%	-$501K	﹤0.01%	5280
2015 Q2	$921K	Buy	303,999 +215,955	+245%	+$607K	﹤0.01%	4613
2015 Q1	$260K	Buy	88,044 +7,126	+9%	+$23.3K	﹤0.01%	5773
2014 Q4	$359K	Sell	80,918 -10,255	-11%	-$48.9K	﹤0.01%	5603
2014 Q3	$470K	Sell	91,173 -9,105	-9%	-$48.6K	﹤0.01%	5332
2014 Q2	$526K	Sell	100,278 -32,700	-25%	-$141K	﹤0.01%	5268
2014 Q1	$553K	Sell	132,978 -15,351	-10%	-$52.6K	﹤0.01%	5195
2013 Q4	$433K	Sell	148,329 -20,254	-12%	-$50.2K	﹤0.01%	5409
2013 Q3	$425K	Sell	168,583 -628	-0.4%	-$1.49K	﹤0.01%	5278
2013 Q2	$352K	Buy	+169,211	New	+$373K	﹤0.01%	5221

Other funds holding ENZ

HFA

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RAM

Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Goldman Sachs's ENZ Position: Q4 2022 in Review

Goldman Sachs sold out of Enzo Biochem, Inc. (ENZ) in Q4 2022, closing a stake of 17,473 shares — an estimated $39K sold.

Goldman Sachs first reported a position in ENZ in Q2 2013 and held it in 38 quarters. The position peaked at $2.28M in Q2 2017. 52 funds tracked by Wall St. Rank hold ENZ as of Q4 2022.

Goldman Sachs reported no remaining Enzo Biochem, Inc. position as of Q4 2022 after selling out during the quarter.
Goldman Sachs sold 17,473 Enzo Biochem, Inc. shares in Q4 2022, an estimated $39K.
Goldman Sachs first reported a position in Enzo Biochem, Inc. in Q2 2013 and held it in 38 quarters.
Goldman Sachs's Enzo Biochem, Inc. position peaked at $2.28M in Q2 2017.
52 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.